Rifater 50 mg/300 mg/120 mg Tablets
Authorisation PA0540/067/001 · Sanofi-Aventis Ireland Limited T/A SANOFI
- Licence holder
- Sanofi-Aventis Ireland Limited T/A SANOFI (all products →)
- Active substances
- Isoniazid, Pyrazinamide, Rifampicin
- Clinical trials
- 11 clinical trials → 10 clinical trials → 20 clinical trials →
- Dosage form
- Tablet
- Route of administration
- Oral use
- ATC codes
- J04AM, J04AM05
- First authorised
- 09/02/1987
- Prescription status
- Product subject to prescription which may not be renewed (A)
- Supply
- Supply through pharmacies only
- Legal basis
- Full application (Article 8(3) of Directive No 2001/83/EC)
Isoniazid: supply and approvals
3 authorised products on the HPRA list contain Isoniazid. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 18 Nov 2026)
- US shortage (FDA)
- No entry in the FDA drug shortage list (checked 18 Nov 2026)
- Germany (BfArM)
- 2 supply notices, e.g. Isozid 0,5 N (8 Dec 2025 to 18 Dec 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
Pyrazinamide: supply and approvals
1 authorised product on the HPRA list contains Pyrazinamide. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 18 Nov 2026)
- US shortage (FDA)
- No entry in the FDA drug shortage list (checked 18 Nov 2026)
- Germany (BfArM)
- No entry in the BfArM supply notices (checked 18 Nov 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
Rifampicin: supply and approvals
7 authorised products on the HPRA list contain Rifampicin. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 18 Nov 2026)
- US shortage (FDA)
- No entry in the FDA drug shortage list (checked 18 Nov 2026)
- Germany (BfArM)
- 1 supply notice, e.g. EREMFAT 600 mg (19 Oct 2026 to 7 Dec 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
About this licence
National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 39 years (since 9 February 1987). The HPRA list marks it as marketed in Ireland.
Other medicines with Isoniazid in Ireland
2 other products on the HPRA list contain Isoniazid, from 1 licence holder; 2 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| Rifinah 150/100 mg Film- Coated Tablets | Sanofi-Aventis Ireland Limited T/A SANOFI | National authorisation (PA) | Marketed |
| Rifinah 300/150 mg Film Coated Tablets | Sanofi-Aventis Ireland Limited T/A SANOFI | National authorisation (PA) | Marketed |
Other medicines with Pyrazinamide in Ireland
No other product on the HPRA list contains Pyrazinamide.
The licence holder
Sanofi-Aventis Ireland Limited T/A SANOFI holds 54 products on the HPRA list, with 22 different active substances; 47 of the products are marked as marketed.
This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.
How this page is built
The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.
- HPRA Authorised Medicines List (open data) ↗ Licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status for this product
This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 19 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.